Jie Zheng (郑杰) Ph.D.

Principal investigator

Neuroscience Research Institute, Peking University

Contact Information

38 Xueyuan Road, Beijing 100191, China

Email: zhengjiie@hsc.pku.edu.cn

Web page: https://www.x-mol.com/groups/zheng_jiie

Academic experience

2020 – present  Assistant Professor (tenure-track), Department of Neurobiology, Peking University.

2020 – 2022  Associate Professor, Department of Pharmacology, Zunyi Medical University.

2017 – 2020  Postdoctoral Fellow, Department of Pathophysiology, Huazhong University of Science and Technology.

2012 – 2017  Ph.D., Department of Neurobiology, Peking University.

2008 – 2012  B.S., Department of Biomedical Engineering, Huazhong University of Science and Technology.

Research interest

Zheng’s lab seeks to restore neurodegeneration in the brain under Alzheimer's disease (AD), the main cause of dementia in the elderly. We use a range of techniques to: (1) investigate pathological mechanisms underlying tau-involved neurodegeneration and cell senescence during the onset and progression of AD, (2) develop novel chimeric drugs targeting tau and other key protein factors, (3) explore pro-neurogenic remedies and cell therapy for AD and related tauopathies.

Publication

# equal contribution, * corresponding author

Qi X#, Yuan S#, Ding J#, Sun W, Shi Y, Xing Y, Liu Z, Yao Y, Fu S, Sun B, Qi X, Xia B, Liu F, Yi M, Mao J, Wan Y*, Zheng J*. Emerging signs of Alzheimer-like tau hyperphosphorylation and neuroinflammation in the brain post recovery from COVID-19. Aging Cell. 2024 Sep 29:e14352. doi: 10.1111/acel.14352

Xiao Y#, Wei L#, Su J#, Lei H, Sun F, Li M, Li S, Wang X*, Zheng J*, Wang JZ*. A tau dephosphorylation-targeting chimera selectively recruits protein phosphatase-1 to ameliorate Alzheimer's disease and tauopathies. Cell Chem Biol. 2024. 31(10):1787-1799.e6

Su J#, Xiao Y#, Wei L, Lei H, Sun F, Wang W, Li S, Wang X*, Zheng J*, Wang JZ*. A new tau dephosphorylation-targeting chimera for the treatment of tauopathies. Acta Pharmacol Sin. 2024. 45(11):2267-2276

Su J#, Xiao Y#, Wei L, Lei H, Sun F, Wang W, Yin J, Xiong R, Li S, Zhang P, Zhou Y, Wang X*, Zheng J*, Wang JZ*. Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies. Sci Bull. 2024. 69(8):1137-1152.

Gao Y#*, Wang YY#, Lei HY, Xu ZD, Li SH, Yu HT, Xie JZ, Zhang ZT, Liu GP, Zhang Y*, Zheng J*, Wang JZ*. A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau. Transl Neurodegener. 2023. 12(1), 51.

Zheng J#*, Tian N#, Liu F, Zhang Y, Su J, Gao Y, Deng M, Wei L, Ye J, Li H, Wang JZ*. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies. Signal Transduct Target Ther. 2021. 6(1):269. (Cover story)

Zheng J#*, Li HL#, Tian N, Liu F, Wang L, Yin YL, Yue LP, Ma LY, Wan Y, Wang JZ*. Interneuron accumulation of phosphorylated tau impairs adult hippocampal neurogenesis by suppressing GABAergic transmission. Cell Stem Cell. 2020. 26(3):331-345.e6.

Zheng J, Jiang YY, Ma LY, Liu FY, Cui S, Cai J, Liao FF, Wan Y*, Yi M*. Adult hippocampal neurogenesis along the dorsoventral axis contributes differentially to environmental enrichment combined with voluntary exercise in alleviating chronic inflammatory pain in mice. J Neurosci. 2017. 37(15):4145-4157.